PSPP - IDENTIFICATION AND VALIDATION OF NOVEL PAIN RELATED ENDPOINTS, NOVEL ANIMAL MODELS OF PAIN AND PROFILING OF INVESTIGATIONAL AGENTS IN RODENT AND NON-RODENT [EXCLUDING (NHP)] SPECIES

PSPP - 新型疼痛相关终点的识别和验证、新型疼痛动物模型以及啮齿类和非啮齿类 [不包括 (NHP)] 物种中研究因子的分析

• 批准号: 10030882
• 负责人: EMER LEAHY
• 金额: $ 312.48万
• 依托单位: PSYCHOGENICS, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-26 至 2024-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10030882
• 关键词: Address; Animal Model; Basic Science; Biological; Clinical Research; Contracts; Development; Devices; Fostering; Goals; In Vitro; Investigation; Metabolic; National Institute of Neurological Disorders and Stroke; Natural Products; Opioid; Pain; Rodent; Translational Research; United States National Institutes of Health; Validation; addiction; in vivo; novel; opioid epidemic; pain model; pre-clinical; response; screening

"The National Institutes of Neurological Disorders and Stroke (NINDS) is establishing the Preclinical Screening Platform for Pain (PSPP) in response to the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) initiative. The HEAL initiative is a trans-NIH effort to fast-track basic, translational, and clinical research in the field of addiction and pain to address the national opioid crisis. The goal of the PSPP is to foster the development of opioid alternatives to treat all types of pain conditions."

国家神经疾病和中风研究所(NINDS)正在建立疼痛临床前筛查平台(PSPP)，以响应美国国立卫生研究院(NIH)帮助结束成瘾长期(Hear)倡议。Hear倡议是一项跨NIH的努力，旨在加快成瘾和疼痛领域的基础、翻译和临床研究，以解决国家阿片类药物危机。PSPP的目标是促进阿片类药物替代品的开发，以治疗所有类型的疼痛状况。